IL6 and neoplasm: The underlying mechanisms are not fully understood but may involve tumor-secreted factors such as vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), or PTHrP, which can promote synovial inflammation and edema, or cross-reactivity of tumor-targeted antibodies leading to immune-mediated joint involvement.